Leucine-rich repeat kinase 2 (LRRK2): an update on the potential therapeutic target for Parkinson's disease.

Kluss, J. H. ORCID: https://orcid.org/0000-0002-6262-6661, Lewis, P. A. ORCID: https://orcid.org/0000-0003-4537-0489 and Greggio, E. ORCID: https://orcid.org/0000-0002-8172-3598 (2022) Leucine-rich repeat kinase 2 (LRRK2): an update on the potential therapeutic target for Parkinson's disease. Expert Opinion on Therapeutic Targets, 26 (6). pp. 537-546. ISSN 1744-7631 doi: 10.1080/14728222.2022.2082937

Abstract/Summary

In this review, we will provide an update on the current status of drugs and other technologies that have emerged in recent years and provide an overview of their efficacy in ameliorating LRRK2 kinase activity and overall safety in animal models and humans. The growth of both target discovery and innovative drug design has sparked a lot of excitement for the future of how we treat Parkinson's disease. Given the immense focus on LRRK2 as a therapeutic target, it is expected within the next decade to determine its therapeutic properties, or lack thereof, for PD.

Item Type	Article
URI	https://reading-clone.eprints-hosting.org/id/eprint/105687
Item Type	Article
Refereed	Yes
Divisions	Life Sciences > School of Chemistry, Food and Pharmacy > School of Pharmacy > Division of Pharmacology
Uncontrolled Keywords	LRRK2, Parkinson’s disease, kinase inhibition, Leucine-rich repeat kinase 2
Publisher	Taylor & Francis
Download/View statistics	View download statistics for this item